Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janneke E W Walraven

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 30, 2025
Inoperable POLE-mutated endometrial carcinoma: treatment beyond current guidelinesBas L R Mandos, Sander Kelderman, Janneke E W Walraven, et al.
British Journal of Clinical Pharmacology|December 2, 2025
Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistatAnnemieke M Peters van Ton, Nielka P van Erp, Annenienke C van de Ven, et al.
Cancer Immunology, Immunotherapy : CII|December 19, 2025
Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancerPrashant Changoer, Chunying Peng, Pepijn van Houten, et al.
European Thyroid Journal|July 24, 2024
Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinomaPepijn van Houten, James Nagarajah, Janneke E W Walraven, et al.
European Thyroid Journal|June 8, 2026
Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort studyPrashant Changoer, Pepijn van Houten, Daniele Ceruti, et al.
Journal of Clinical Medicine|May 25, 2024
Development and Internal Validation of Nomograms for Survival of Advanced Epithelial Ovarian Cancer Based on Established Prognostic Factors and Hematologic ParametersSherin Abdo Said, Joanna IntHout, Judith E den Ouden, et al.
BMC Health Services Research|June 27, 2022
Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic reviewJanneke E W Walraven, Olga L van der Hel, J J M van der Hoeven, et al.
BMC Medical Education|June 27, 2022
Preparing tomorrow's medical specialists for participating in oncological multidisciplinary team meetings: perceived barriers, facilitators and training needsJanneke E W Walraven, Renske van der Meulen, Jacobus J M van der Hoeven, et al.
BMJ Open Quality|February 9, 2023
Facilitators and barriers to conducting an efficient, competent and high-quality oncological multidisciplinary team meetingJanneke E W Walraven, Rob H A Verhoeven, Renske van der Meulen, et al.
Frontiers in Oncology|June 5, 2023
Pros and cons of streamlining and use of computerised clinical decision support systems to future-proof oncological multidisciplinary team meetingsJanneke E W Walraven, Rob H A Verhoeven, Jacobus J M van der Hoeven, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 30, 2025
Inoperable POLE-mutated endometrial carcinoma: treatment beyond current guidelinesBas L R Mandos, Sander Kelderman, Janneke E W Walraven, et al.
British Journal of Clinical Pharmacology|December 2, 2025
Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistatAnnemieke M Peters van Ton, Nielka P van Erp, Annenienke C van de Ven, et al.
Cancer Immunology, Immunotherapy : CII|December 19, 2025
Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancerPrashant Changoer, Chunying Peng, Pepijn van Houten, et al.
European Thyroid Journal|July 24, 2024
Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinomaPepijn van Houten, James Nagarajah, Janneke E W Walraven, et al.
European Thyroid Journal|June 8, 2026
Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort studyPrashant Changoer, Pepijn van Houten, Daniele Ceruti, et al.
Journal of Clinical Medicine|May 25, 2024
Development and Internal Validation of Nomograms for Survival of Advanced Epithelial Ovarian Cancer Based on Established Prognostic Factors and Hematologic ParametersSherin Abdo Said, Joanna IntHout, Judith E den Ouden, et al.
BMC Health Services Research|June 27, 2022
Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic reviewJanneke E W Walraven, Olga L van der Hel, J J M van der Hoeven, et al.
BMC Medical Education|June 27, 2022
Preparing tomorrow's medical specialists for participating in oncological multidisciplinary team meetings: perceived barriers, facilitators and training needsJanneke E W Walraven, Renske van der Meulen, Jacobus J M van der Hoeven, et al.
BMJ Open Quality|February 9, 2023
Facilitators and barriers to conducting an efficient, competent and high-quality oncological multidisciplinary team meetingJanneke E W Walraven, Rob H A Verhoeven, Renske van der Meulen, et al.
Frontiers in Oncology|June 5, 2023
Pros and cons of streamlining and use of computerised clinical decision support systems to future-proof oncological multidisciplinary team meetingsJanneke E W Walraven, Rob H A Verhoeven, Jacobus J M van der Hoeven, et al.
Pageof 2